- Home
- CEV vs ANL Comparison
CEV vs ANL Comparison
Compare CEV & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- ANL
- Stock Information
- Founded
- CEV 1999
- ANL 2004
- Country
- CEV United States
- ANL Cayman Islands
- Employees
- CEV N/A
- ANL N/A
- Industry
- CEV Finance/Investors Services
- ANL
- Sector
- CEV Finance
- ANL
- Exchange
- CEV Nasdaq
- ANL Nasdaq
- Market Cap
- CEV 67.8M
- ANL 73.8M
- IPO Year
- CEV N/A
- ANL 2023
- Fundamental
- Price
- CEV $9.62
- ANL $1.77
- Analyst Decision
- CEV
- ANL Strong Buy
- Analyst Count
- CEV 0
- ANL 2
- Target Price
- CEV N/A
- ANL $9.00
- AVG Volume (30 Days)
- CEV 19.6K
- ANL 10.1K
- Earning Date
- CEV 01-01-0001
- ANL 06-10-2025
- Dividend Yield
- CEV 4.23%
- ANL N/A
- EPS Growth
- CEV N/A
- ANL N/A
- EPS
- CEV 0.36
- ANL N/A
- Revenue
- CEV N/A
- ANL N/A
- Revenue This Year
- CEV N/A
- ANL N/A
- Revenue Next Year
- CEV N/A
- ANL N/A
- P/E Ratio
- CEV $29.36
- ANL N/A
- Revenue Growth
- CEV N/A
- ANL N/A
- 52 Week Low
- CEV $8.83
- ANL $1.10
- 52 Week High
- CEV $10.91
- ANL $8.88
- Technical
- Relative Strength Index (RSI)
- CEV 42.26
- ANL 42.48
- Support Level
- CEV $9.56
- ANL $1.71
- Resistance Level
- CEV $9.82
- ANL $2.10
- Average True Range (ATR)
- CEV 0.08
- ANL 0.08
- MACD
- CEV -0.01
- ANL 0.00
- Stochastic Oscillator
- CEV 32.35
- ANL 0.00
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.